https://hsrc.himmelfarb.gwu.edu/gwhpubs/3894/
"Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas I" by Sriram Venneti, Abed...
UNLABELLED: Patients with H3K27M-mutant diffuse midline glioma (DMG) have no proven effective therapies. ONC201 has recently demonstrated efficacy in these...
https://clinicaltrials.med.nyu.edu/cancer/clinicaltrial/1454/expanded-access-onc201-patients/?qd=35300665
Expanded Access to ONC201 for Patients with H3 K27M-mutant and/or Midline Gliomas | NYU Langone...
New life-saving treatments for in clinical trial on Expanded Access to ONC201 for Patients with H3 K27M-mutant and/or Midline Gliomas
https://researchexperts.utmb.edu/en/publications/first-in-human-clinical-trial-of-oral-onc201-in-patients-with-ref/
First-in-human clinical trial of oral ONC201 in patients with refractory solid tumors - UTMB Health...
https://www.oncotarget.com/article/2890/text/
The angular structure of ONC201 a TRAIL pathwayinducing compound determines its potent anticancer...
https://doi.org/10.18632/oncotarget.2890 Jessica Wagner, Christina Leah Kline, Richard S. Pottorf, Bhaskara Rao Nallaganchu, Gary L. Olson, David T. Dicker,...